Challenges to the measurement of estradiol: An endocrine society position statement

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 4, 2013, Pages 1376-1387

  Rosner, William ^a   Hankinson, Susan E ^b,c   Sluss, Patrick M ^d   Vesper, Hubert W ^e   Wierman, Margaret E ^f,g  

^a St Luke's Roosevelt Hospital Center ^*  (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; AROMATASE INHIBITOR; CHORIONIC GONADOTROPIN; ESTRADIOL; ESTRIOL; ESTROGEN; FOLLITROPIN; SEX HORMONE;

ACCURACY; AMENORRHEA; ANALYTIC METHOD; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE MASS; BREAST CANCER; ENZYME IMMUNOASSAY; ESTRADIOL BLOOD LEVEL; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONAL THERAPY; HORMONE DETERMINATION; HUMAN; HYPOGONADISM; IMMUNOASSAY; INFERTILITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MENOPAUSE; MENSTRUAL CYCLE; MUSCLE STRENGTH; OVULATION INHIBITION; PREGNANCY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONTENT; PROTEIN FUNCTION; PUBERTY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

DIAGNOSTIC ERRORS; DIAGNOSTIC TECHNIQUES, ENDOCRINE; ENDOCRINOLOGY; ESTRADIOL; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL PRACTICE; RESEARCH DESIGN; SOCIETIES, MEDICAL;

EID: 84876229350     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3780     Document Type: Article

References (87)

1. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92:405-413.
2. CDC workshop report improving steroid hormone measurements in patient care and research translation. Steroids. 2008;73:1285-1352.
3. Rosner W, Vesper H. Preface. CDC workshop report improving steroid hormone measurements in patient care and research translation. Steroids. 2008;73:1285.
4. Data replication and reproducibility. Science. 2011;334:1225-1233.
5. Abraham GE, Odell WD. Solid-phase immunoassay for estradiol 17-β: a semi-automated approach. In: Peron FG, Caldwell BV, eds. Immunologic methods in steroid determination. New York: Appelton-Century-Crofts; 1970;87-112.
6. Abraham GE. Solid-phase immunoassay for estradiol 17-β. J Clin Endocrinol Metab. 1969;29:866-870.
7. Stanczyk FZ, Jurow J, Hsing AW. Limitations of direct immunoassays for measuring circulating estradiol levels in postmenopausal women and men in epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2010;19:903-906.
8. Laboratory instrumentation product guide: immunoassay analyzers. Northfiled, Illinois: College of American Pathologists; 2011; 17-54.
9. Thienpont LM, Verhaeghe PG, Van Brussel KA, De Leenheer AP. Estradiol-17 β quantified in serum by isotope dilution-gas chromatography-mass spectrometry: reversed-phase C18 high-performance liquid chromatography compared with immuno-affinity chromatography for sample pretreatment. Clin Chem. 1988;34: 2066-2069.
10. Stanczyk FZ, Clarke NJ. Advantages and challenges of mass spectrometry assays for steroid hormones. J Steroid Biochem Mol Biol. 2010;121:491-495.
11. Giese RW. Measurement of endogenous estrogens: analytical challenges and recent advances. J Chromatogr A. 2003;1000:401-412.
12. Thienpont LM, Van UK, Blincko S, et al. State-of-the-art of serum testosterone measurement by isotope dilution-liquid chromatography-tandem mass spectrometry. Clin Chem. 2008;54:1290-1297.
13. Vesper HW, Bhasin S, Wang C, et al. Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods. Steroids. 2009;74:498-503.
14. Demers LM. Testosterone and estradiol assays: current and future trends. Steroids. 2008;73:1333-1338.
15. Lepine J, Bernard O, Plante M, et al. Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphosphoglucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab. 2004;89:5222-5232.
16. Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF. Catechol-O- methyltransferase (COMT)-mediated metabolism of catechol estrogens. Cancer Res. 2001;61:6716-6722.
17. Lippert TH, Seeger H, Mueck AO. The impact of endogenous estradiol metabolites on carcinogenesis. Steroids. 2000;65:357-369.
18. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003;144:3382-3398.
19. Ekins R, Edwards P. On the meaning of "sensitivity". Clin Chem. 1997;43:1824-1831.
20. Mueck AO, Seeger H, Lippert TH. Estradiol metabolism and malignant disease. Maturitas. 2002;43:1-10.
21. Schioler V, Thode J. Six direct radioimmunoassays of estradiol evaluated. Clin Chem. 1988;34:949-952.
22. Nisbet JA, Jomain PA. Discrepancies in plasma estradiol values obtained with commercial kits. Clin Chem. 1987;33:1672.
23. Thomas CM, van den Berg RJ, Segers MF. Measurement of serum estradiol: comparison of three "direct" radioimmunoassays and effects of organic solvent extraction. Clin Chem. 1987;33:1946-1947.
24. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-2559.
25. Dowsett M, Folkerd E. Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res. 2005;7:1-4.
26. Cao Z, Swift TA, West CA, Rosano TG, Rej R. Immunoassay of estradiol: unanticipated suppression by unconjugated estriol. Clin Chem. 2004;50:160-165.
27. Reinsberg J, Batz O, Bertsch T, et al. Precision and long-term stability of different estradiol immunoassays assessed in a multi-center quality control study. Clin Lab. 2009;55:201-206.
28. Middle JG. External quality assessment of steroid hormone assays in the United Kingdom. Ann Ist Super Sanita. 1991;27:459-465.
29. Yang DT, Owen WE, Ramsay CS, Xie H, Roberts WL. Performance characteristics of eight estradiol immunoassays. Am J Clin Pathol. 2004;122:332-337.
30. Coucke W, Devleeschouwer N, Libeer JC, Schiettecatte J, Martin M, Smitz J. Accuracy and reproducibility of automated estradiol-17β and progesterone assays using native serum samples: results obtained in the Belgian external assessment scheme. Hum Reprod. 2007;22:3204-3209.
31. Sluss PM, Hayes FJ, Adams JM, et al. Mass spectrometric and physiological validation of a sensitive, automated, direct immunoassay for serum estradiol using the Architect. Clin Chim Acta. 2008;388: 99-105.
32. Thienpont LM, De Leenheer AP. Efforts by industry toward standardization of serum estradiol-17 β measurements. Clin Chem. 1998;44:671-674.
33. Thienpont L. Meeting report: First and Second Estradiol International Workshops. Clin Chem. 1996;42:1122-1124.
34. Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev. 2007;16:1713-1719.
35. Raff H, Sluss PM. Pre-analytical issues for testosterone and estradiol assays. Steroids. 2008;73:1297-1304.
36. Bay K, Andersson AM, Skakkebaek NE. Estradiol levels in prepubertal boys and girls - analytical challenges. Int J Androl. 2004;27: 266-273.
37. Carlstrom K. Low endogenous estrogen levels - analytical problems and tissue sensitivity. Acta Obstet Gynecol Scand Suppl. 1996;163: 11-15.
38. Ikegami S, Moriwake T, Tanaka H, et al. An ultrasensitive assay revealed age-related changes in serum oestradiol at low concentrations in both sexes from infancy to puberty. Clin Endocrinol (Oxf). 2001;55:789-795.
39. Klein KO, Baron J, Colli MJ, McDonnell DP, Cutler GB Jr. 1994 Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest. 94:2475-2480.
40. Larmore KA, O'Connor D, Sherman TI, Funanage VL, Hassink SG, Klein KO. Leptin and estradiol as related to change in pubertal status and body weight. Med Sci Monit. 2002;8:CR206-CR210.
41. Rosner W. La plus ça change, la plus c'est la même chose - will bioassays make a comeback? J Clin Endocrinol Metab. 2001;86: 1898-1899.
42. Shi L, Remer T, Buyken AE, Hartmann MF, Hoffmann P, Wudy SA. Prepubertal urinary estrogen excretion and its relationship with pubertal timing. Am J Physiol Endocrinol Metab. 2010;299:E990-E997.
43. Fossa SD, Klepp O, Barth E, Aakvaag A, Kaalhus O. Endocrinological studies in patients with metastatic malignant testicular germ cell tumours. Int J Androl. 1980;3:487-501.
44. Large DM, Anderson DC. Twenty-four hour profiles of circulating androgens and oestrogens in male puberty with and without gynecomastia. Clin Endocrinol (Oxf). 1979;11:505-521.
45. Soules MR, McLachlan RI, Ek M, Dahl KD, Cohen NL, Bremner WJ. Luteal phase deficiency: characterization of reproductive hormones over the menstrual cycle. J Clin Endocrinol Metab. 1989;69: 804-812.
46. Anttila L, Koskinen P, Irjala K, Kaihola HL. Reference intervals for serum sex steroids and gonadotropins in regularly menstruating women. Acta Obstet Gynecol Scand. 1991;70:475-481.
47. Reginster JY, Sarlet N, Deroisy R, Albert A, Gaspard U, Franchimont P. Minimal levels of serum estradiol prevent postmenopausal bone loss. Calcif Tissue Int. 1992;51:340-343.
48. Rothman MS, Carlson NE, Xu M, et al. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids. 2011;76: 177-182.
49. Massart C, Gibassier J, Laurent MC, Le Lannou DL. Analytical performance of a new two-step ADVIA Centaur estradiol immunoassay during ovarian stimulation. Clin Chem Lab Med. 2006;44: 105-109.
50. Hegab HM, Schindler AE. The prognostic value of serum inhibin, 17 β-estradiol and progesterone in cases of hydatidiform mole. Gynecol Endocrinol. 2004;18:107-113.
51. Doria A, Iaccarino L, Sarzi-Puttini P, et al. Estrogens in pregnancy and systemic lupus erythematosus. Ann NY Acad Sci. 2006;1069: 247-256.
52. Randolph JF Jr, Zheng H, Sowers MR, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab. 2011;96:746-754.
53. Lee JS, Ettinger B, Stanczyk FZ, et al. Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab. 2006;91:3791-3797.
54. Santen RJ, Demers L, Ohorodnik S, et al. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids. 2007;72:666-671.
55. Hsing AW, Stanczyk FZ, Belanger A, et al. Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry. Cancer Epidemiol Biomarkers Prev. 2007;16:1004-1008.
56. Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density inmen and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab. 1998;83:2266-2274.
57. Khosla S, Amin S, Singh R, Atkinson E, Melton LJ III, Riggs B. Comparison of sex steroid measurements in men by immunoassay versus mass spectroscopy and relationships with cortical and trabecular volumetric bone mineral density. Osteoporos Int. 2008;19: 1465-1471.
58. Auyeung TW, Lee JS, Kwok T, et al. Testosterone but not estradiol level is positively related to muscle strength and physical performance independent of muscle mass: a cross-sectional study in 1489 older men. Eur J Endocrinol. 2011;164:811-817.
59. Vandenput L, Mellstrom D, Karlsson MK, et al. Serum estradiol is associated with lean mass in elderly Swedish men. Eur J Endocrinol. 2010;162:737-745.
60. Trabado S, Maione L, Salenave S, et al. Estradiol levels in men with congenital hypogonadotropic hypogonadism and the effects of different modalities of hormonal treatment. Fertil Steril. 2011;95: 2324-2329.e1-e3
61. Kawashima H, Nakatani T. Involvement of estrogen receptors in prostatic diseases. Int J Urol. 2012;19:512-522.
62. Agirbasli M, Agaoglu NB, Orak N, et al. Sex hormones, insulin resistance and high-density lipoprotein cholesterol levelsinchildren. Horm Res Paediatr. 2010;73:166-174.
63. Bernstein L, Lipworth L, Ross RK, Trichopoulos D. Correlation of estrogen levels between successive pregnancies. Am J Epidemiol. 1995;142:625-628.
64. Pinheiro SP, Holmes MD, Pollak MN, Barbieri RL, Hankinson SE. Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev. 2005;14:2147-2153.
65. Vaidya D, Dobs A, Gapstur SM, et al. The association of endogenous sex hormones with lipoprotein subfraction profile in the Multi-Ethnic Study of Atherosclerosis. Metabolism. 2008;57:782-790.
66. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006;354:270-282.
67. Key T, Appleby P, Barnes I, Reeves G; Endogenous Hormones and Breast Cancer Collaborative Group. Endogenoussex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606-616.
68. Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer. 2005;12: 1071-1082.
69. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004;96:1856-1865.
70. Key TJ. Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids. 2011;76:812-815.
71. Onland-Moret NC, Kaaks R, van Noord PA, et al. Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer. 2003;88:1394-1399.
72. Dorgan JF, Baer DJ, Albert PS, et al. Serum hormones and the alcohol-breast cancer association in postmenopausal women. J Natl Cancer Inst. 2001;93:710-715.
73. Hamajima N, Hirose K, Tajima K, et al; Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002;87:1234-1245.
74. Beckmann L, Husing A, Setiawan VW, et al. Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the Breast and Prostate Cancer Cohort Consortium (BPC3). J Clin Endocrinol Metab. 2011;96:E360-E367.
75. Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2008;15:485-497.
76. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk ofendometrial cancer inpostmenopausal women. Int J Cancer. 2004;108:425-432.
77. Lee JS, Yaffe K, Lui LY, et al; Study of Osteoporotic Fractures Group. Prospective study of endogenous circulating estradiol and risk of stroke in older women. Arch Neurol. 2010;67:195-201.
78. Chen Y, Zeleniuch-Jacquotte A, Arslan AA, et al. Endogenous hormones and coronary heart disease in postmenopausal women. Atherosclerosis. 2011;216:414-419.
79. Laughlin GA, Kritz-Silverstein D, Barrett-Connor E. Endogenous oestrogens predict 4-year decline in verbal fluency in postmenopausal women: the Rancho Bernardo Study. Clin Endocrinol (Oxf). 2010;72:99-106.
80. Roddam AW, Appleby P, Neale R, et al. Association between endogenous plasma hormone concentrations and fracture risk in men and women: the EPIC-Oxford prospective cohort study. J Bone Miner Metab. 2009;27:485-493.
81. Chatterton RT Jr, Parker NP, Habe-Evans M, Bryk M, Scholtens DM, Khan SA. Breast ductal lavage for assessment of breast cancer biomarkers. Horm Cancer. 2010;1:197-204.
82. Hankinson SE, Manson JE, London SJ, Willett WC, Speizer FE. Laboratory reproducibility of endogenous hormone levels in post-menopausal women. Cancer Epidemiol Biomarkers Prev. 1994;3: 51-56.
83. Key T, Appleby P, Reeves G, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer. 2011;105:709-722.
84. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170-183.
85. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1998;339:733-738.
86. McGuire WL. Estrogen receptors in human breast cancer. J Clin Invest. 1973;52:73-77.
87. Janne O, Kontula K, Vihko R, Pystynen P, Auvinen O, Lauslahti K. Steroid binding properties of estradiol receptors in human breast cancer. Med Biol. 1975;53:214-223.